September 17, 2021 -- Dutch biopharmaceutical startup Oxitope Pharma has officially launched. The company was founded and seed financed by Forbion.
Oxitope is dedicated to the development of antibody-based medicines for the treatment of diseases caused by oxidative stress, company officials said.
Co-founders Drs. Joe Witztum and Sam Tsimikas are professors at the University of California, San Diego. Witztum and Tsimikas have investigated how oxidative stress can induce the formation of oxidation-specific epitopes (OSEs). OSEs are believed to be key drivers of unhealthy aging and can play a key role in inflammatory, cardiovascular, and fibrotic diseases.
Oxitope aims to provide therapeutics to treat a range of cardiovascular, inflammatory, and fibrotic indications, the company said.
Copyright © 2021 scienceboard.net